Tony Mok
莫树锦
MD, FRCP, FASCO
Li Shu Fan Medical Foundation Professor of Clinical Oncology临床肿瘤学李树芬医学基金教授
👥Biography 个人简介
Prof. Tony Mok is one of the world's most celebrated thoracic oncologists, best known for leading the IPASS trial that revolutionized lung cancer treatment by establishing EGFR-targeted therapy for Asian patients. A prolific trialist and ASCO past-president candidate, his work has transformed precision oncology globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IPASS Trial
Led the landmark IPASS trial demonstrating superior PFS of gefitinib over chemotherapy in EGFR-mutated NSCLC, establishing molecular selection as the foundation of modern lung cancer therapy.
Osimertinib Development
Co-led the FLAURA trial establishing osimertinib as first-line standard of care for EGFR-mutated NSCLC, defining the current global treatment paradigm.
Global Trial Leadership
Chaired or co-chaired over 50 international phase III trials, shaping global lung cancer treatment standards and mentoring a generation of Asian oncology researchers.
Representative Works 代表性著作
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (IPASS)
New England Journal of Medicine (2009)
Landmark trial that transformed lung cancer management by proving EGFR mutation-positive patients derive superior benefit from EGFR TKIs over chemotherapy.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (FLAURA)
New England Journal of Medicine (2018)
Established osimertinib as the global first-line standard for EGFR-mutated NSCLC with superior PFS and CNS penetration over earlier-generation TKIs.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 莫树锦 的研究动态
Follow Tony Mok's research updates
留下邮箱，当我们发布与 Tony Mok（The Chinese University of Hong Kong）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment